Results from a 36-participant Phase 1 dose-escalation clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of Marinus Pharmaceuticals� $MRNS lead product candidate ganaxolone as an ascending bolus dose or continuous infusion achieved dose levels targeted for efficacy in patients with status epilepticus, an emergency-situation for of epilepsy characterized by prolonged or recurrent grand mal seizures. The data were shown at the 141st Annual Meeting of the American Neurological Association in Baltimore, MD. The Phase 2 clinical trial will start in 2017.